One-year retrospective analysis of anti-FXa apixaban and rivaroxaban levels demonstrates utility for management decisions in various urgent and nonurgent clinical situations.

Jennifer A WoyachJoshua LewisJessica GrandoniKatelyn W SylvesterThomas D BernierClara TingRebecca SekKathleen BallardJean M ConnorsElisabeth M Battinelli

Published in: American journal of clinical pathology (2023)

Although clinical situations are complex, DOAC testing facilitates clinical decision-making, including reversal, justifying more widespread implementation of these assays.

Keyphrases

decision making
venous thromboembolism
healthcare
single cell
direct oral anticoagulants